MHC class II marks stronger immune response and longer survival in ovarian cancer

A new study is offering critical insights into why some women with high-grade serous ovarian cancer—the most aggressive form of the disease—experience better outcomes than others. Researchers have linked the presence of a molecule called MHC class II in tumor cells to stronger immune responses and increased survival rates.

Unlocking the Immune Response

The research, led by the University of Helsinki, examined ovarian cancer tissue from over 280 women. Findings suggest that the area where the tumor meets healthy tissue—the “front line”—is a key battleground where the body’s immune system attempts to contain the disease. Immune cells gathering in groups at this border were associated with improved patient outcomes.

Did You Know? Researchers created detailed maps of over 1000 ovarian cancer tissues, focusing on individual cell arrangements to better understand the immune response.

Cancer Cells and the Immune System

The study revealed that cancer cells can actively influence the behavior of the immune system in their vicinity. Researchers were surprised to discover MHC class II, a molecule typically used by immune cells to signal threats, also present on some cancer cells themselves. Higher levels of MHC class II correlated with stronger immune responses and more favorable outcomes, independent of other known risk factors.

“We were surprised to see cancer cells using a signal normally reserved for the immune system,” said Anniina Färkkilä, study’s lead researcher and specialist in gynecology at the University of Helsinki.

Implications for Immunotherapy

To further investigate the role of MHC class II, researchers tested tumor samples grown in the lab. They found that when tumors expressed MHC class II, immune cells were more effective at attacking the cancer following immunotherapy. Blocking the MHC class II signal, however, weakened the immune response.

Expert Insight: The discovery of MHC class II’s role suggests a potential pathway for more targeted cancer treatment. Identifying patients whose tumors express this molecule could allow clinicians to better select individuals who are most likely to benefit from immunotherapy, maximizing treatment effectiveness.

These results suggest that immunotherapies may be more effective in patients whose tumors express MHC class II. Boosting MHC class II expression could also potentially enhance a patient’s response to immunotherapy.

Future Directions

The findings, published in Cancer Discovery on February 9, 2026, demonstrate the potential of harnessing the immune system for more personalized ovarian cancer treatment. Further research could explore methods to increase MHC class II expression in tumors that lack it, potentially broadening the pool of patients who could benefit from immunotherapy. It is also possible that additional research will reveal other molecules involved in the interplay between ovarian cancer cells and the immune system.

Frequently Asked Questions

What is MHC class II?

MHC class II is a molecule normally used by immune cells to alert the body to external threats. This study found it present on some cancer cells, where it appears to influence the immune response.

What role does the “front line” play in ovarian cancer?

The “front line,” or the area where the tumor meets healthy tissue, is a crucial place where the body’s defense tries to stop the disease from spreading. Immune cells gathering in this area were linked to better patient outcomes.

How was immunotherapy tested in this study?

Researchers used tumor samples grown from patients in the lab. They found that immune cells were better able to attack cancer cells after immunotherapy when the tumors carried MHC class II.

How might a deeper understanding of the immune system’s response to ovarian cancer change treatment strategies in the years to come?